Everything from common medications and supplements, like statins and herbs, to novel immunological and hematological interventions, like oncolytic viruses and adoptive t-cell therapies, are being explored to target KRAS mutations in CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.